Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 5/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 10/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.43 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17599319 | 0.84 | ACLY (0.46) | FABP4FABP5KMT2AACLYPTK2B | |
| SCHEMBL17599400 | 0.84 | KMT2A (0.49) | FABP4FABP5KMT2AACLYPTK2B | |
| SCHEMBL17599337 | 0.82 | PTK2B (0.50) | FABP4FABP5KMT2AACLYPTK2B | |
| SCHEMBL17599310 | 0.82 | PTK2B (0.53) | FABP4FABP5KMT2AACLYPTK2B | |
| SCHEMBL17599402 | 0.82 | BRD4 (0.52) | FABP4FABP5KMT2AACLYPTK2B | |
| SCHEMBL17599317 | 0.80 | FABP4 (0.52) | FABP4FABP5KMT2AACLYPTK2B | |
| SCHEMBL17599379 | 0.79 | ACLY (0.54) | FABP4KMT2AACLYPTK2BSLC16A3 | |
| SCHEMBL17599360 | 0.78 | ITGA1 (0.56) | FABP4FABP5KMT2AACLYPTK2B | |
| SCHEMBL17599340 | 0.78 | SLC16A3 (0.58) | FABP4KMT2AACLYPTK2BSLC16A3 | |
| SCHEMBL17599403 | 0.77 | WDR5 (0.49) | FABP4KMT2AACLYPTK2BSLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2998294-A1 | Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |
| EP-2998294-A1 | Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |